USSTOCK.TODAY
Pre-Market
Log in Sign up

Travere Therapeutics Reports $224.6 Million in Third Quarter Revenue

The Motley Fool +1 · ·by G4L

TVTX
TVTX Travere Therapeutics Inc
$51.99 +0.70%
View chart & analysis →
  1. 1Travere Therapeutics recorded total revenue of $224.6 million in the third quarter.
  2. 2Travere Therapeutics achieved FILSPARI net revenue of $202 million in the third quarter.
  3. 3Travere Therapeutics reaffirmed its annual FILSPARI revenue target of over $3 billion by 2033.

So what's the key point?

Travere Therapeutics generated $224.6 million in revenue during the third quarter. Sales from the drug FILSPARI accounted for a large portion, and the company reaffirmed its revenue targets through 2033.

Source The Motley Fool +1 · View original ↗

Related 3-line summaries

Travere Therapeutics beats consensus with $224.56 million in revenue Earnings Whispers · Nov 3Guardant Health Ordered to Pay $245.2M for DNA Sequencing Patent Infringement Investor's Business Daily +1 · Aug 25onsemi Announces Q3 Results · AI Data Center Revenue Surges The Motley Fool +1 · Nov 3
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news